Fierce Pharma

JANUARY 8, 2024

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

Prospecting 294

Prospecting Biopharma Pharma Healthcare 294

European Pharmaceutical Review

DECEMBER 30, 2023

The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In

Biopharma 105

Biopharma Marketing Prospecting Pharmaceutical 105

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. Evaluate’s VC data show quarter-over-quarter drops in the number of biopharma companies raising private cash and in the amount of money raised.

Biopharma 111

Biopharma Pharma Marketing Management 111

The Marketing Advantage

FEBRUARY 26, 2024

February 26, 2024 The rare disease and orphan drug space remains one of the most difficult markets in which to set accurate and equitable territory-level goals. In this blog post, we will explore how to set territory-level goals for a rare disease product to ensure your product reaches and improves outcomes for as many patients as possible.

Sales 52

Sales Consulting Prospecting Biopharma 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

DECEMBER 14, 2023

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111

Pharma Government Pharmacology Healthcare 111

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? Sticking to the cell and gene therapy space, what’s your main prediction for 2024?

Manufacturing 97

Manufacturing Food and Drug Administration Biopharma Marketing 97